{"resourceType": "Group", "meta": {"versionId": "8", "lastUpdated": "2024-09-29T17:32:12.502Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/cohort-definition"]}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "CohortDefinition: T2DM-specific criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279346. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279346. Computable resource at: https://fevir.net/resources/Group/279346."}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-title", "valueString": "CohortDefinition: T2DM-specific criteria"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-url", "valueUri": "https://fevir.net/resources/Group/279346"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-publisher", "valueString": "Computable Publishing LLC"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-copyright", "valueMarkdown": "https://creativecommons.org/licenses/by-nc-sa/4.0/"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-contact", "valueContactDetail": {"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method", "valueCode": "all-of"}], "id": "279346", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "279346", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "definitional", "characteristic": [{"code": {"coding": [{"system": "http://snomed.info/sct", "code": "64572001", "display": "Disease (disorder)"}]}, "valueCodeableConcept": {"coding": [{"system": "http://snomed.info/sct", "code": "44054006", "display": "Diabetes mellitus type 2 (disorder)"}]}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria"}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method", "valueCodeableConcept": {"text": "based on the World Health Organization (WHO) diagnostic criteria"}}]}, {"code": {"text": "Medication exposure"}, "valueCodeableConcept": {"text": "Daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs)\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine"}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine"}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-duration-duration", "valueDuration": {"comparator": ">=", "value": 1, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}}]}, {"code": {"coding": [{"system": "http://snomed.info/sct", "code": "397669002", "display": "Age"}]}, "valueRange": {"low": {"value": 20, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}, "high": {"value": 70, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Are between 20 and 70 years old at the time of informed consent"}, {"extension": [{"url": "contextCode", "valueCodeableConcept": {"coding": [{"system": "http://snomed.info/sct", "code": "182771004", "display": "Informed consent"}]}}, {"url": "offset", "valueDuration": {"value": 0}}], "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"}]}, {"code": {"coding": [{"system": "http://loinc.org", "code": "39156-5", "display": "Body mass index (BMI) [Ratio]"}]}, "valueRange": {"low": {"value": 18.5, "unit": "kilogram per square meter (kg/m2)", "system": "http://unitsofmeasure.org", "code": "kg/m2"}, "high": {"value": 35, "unit": "kilogram per square meter (kg/m2)", "system": "http://unitsofmeasure.org", "code": "kg/m2"}}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening"}, {"extension": [{"url": "contextCode", "valueCodeableConcept": {"text": "screening"}}, {"url": "offset", "valueDuration": {"value": 0}}], "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"}]}], "description": "i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening", "modifierExtension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-status", "valueCode": "active"}], "type": "animal"}